PCRX (pacira.com) Market Value to Book Value Ratio

Official company branding of Pacira Pharmaceuticals (PCRX)

The price indicator on the Pacira BioSciences (PCRX) chart reflects the dynamics of a business that relies on its own sterile manufacturing facilities in the UK and US to produce analgesics. However, generic pressure on the drug Exparel threatens future revenues, which currently stand at 2.17. Simultaneously, Pacira BioSciences (PCRX) is implementing eco-friendly packaging and optimizing plant energy costs as part of its ESG strategy.

PCRX Pacira Corp: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for Pacira Pharmaceuticals (PCRX)

- price and consensus price forecast:
Stock Quotes Pacira BioSciences|PCRX - Broker Consensus Forecast
- market capitalization data:
Market Value Pacira|PCRX - Full Business Value
- book capitalization data:
Book Value per Share Pacira BioSciences|PCRX - Accounting Value of Company|Market Capitalization to Book Value Ratio pacira.com|PCRX - Company Total Assets
- debt and liquidity data:
Debt to Equity Pacira BioSciences|PCRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Pacira|PCRX - Company Total Debt|Debts to Book Capitalization Pacira
Initial company analysis:Pacira BioSciences - PCRX
Original product of Pacira

This indicator determines the market revaluation of net assets by comparing the stock price to the company's actual capital to filter out volatile noise. Analyzing the market capitalization-to-book value ratio allows for an assessment of the stability of Pacira BioSciences (PCRX), where the asset premium is justified by the unique patent protection of Exparel and leadership in the non-opioid pain management segment.

Main competitors

Market Cap to Net Assets Ratio Haleon plc|KVUE (kenvue.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Verona Pharma VRNA|Market Capitalization to Net Assets Jyong Biotech Limited|Ligand Pharma (LGND) - Market Capitalization to Book Value Ratio|Market Value to Book Value Amneal Corp (AMRX)|Market Capitalization to Book Value Ratio PRGO (Perrigo Company plc)|alvotech.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Liquidia (LQDA)|GLPG: Market Value to Book Value|ANIP (ANI Pharma) - Market Value to Book Value Ratio|Afrezza (MNKD) - Market Cap to Net Assets Ratio|AMPH (Amphastar Pharmaceuticals) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ars-pharma.com (SPRY)|Theravance Biopharma, Inc. (TBPH) - Market Cap to Net Assets Ratio|Market Value to Book Value AQST (Aquestive Therapeutics Inc)|SCPH: Market Value to Book Value Ratio|TECX - Market-to-Book Ratio|Market Cap to Net Assets Ratio Tonix Pharmaceuticals TNXP|SXTC - Market Cap to Book Value Multiple|Market Capitalization to Book Value Ratio eupraxiapharma.com EPRX|BioHarvest Sciences, Inc. (BHST) - Market Value to Book Value|Market Capitalization to Book Value Ratio EXOZ (Invizyne Technologies, Inc.)|Market-to-Book Ratio ORMP|Entera Bio Ltd. (ENTX) - Market Value to Book Value Ratio|Market Value to Book Value HYFT (ipatherapeutics.com)|ABVC BioPharma, Inc. (ABVC) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Cumberland Pharmaceuticals Inc CPIX|Quantum BioPharma Limited - Market Capitalization to Book Value Ratio|FGEN - Market Capitalization to Book Value Ratio|TELO (Telomir Pharmaceuticals) - Market Capitalization to Book Value Ratio|Rani Therapeutics Holdings, Inc. (RANI) - Market Cap to Net Assets Ratio|SNYR: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value RLYB|Lexaria Bioscience (LEXX) - Market Value to Book Value Ratio|Market Value to Book Value Pulmatrix Corporation (PULM)|Market Capitalization to Book Value Ratio PTHL (Pheton Holdings)|APM - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Lyra Therapeutics (LYRA)|IBO - Market Value to Book Value|tnfpharma.com (TNFA) - Market Capitalization to Book Value Ratio|cbdMD (YCBD) - Market Value to Book Value Ratio|PRFX: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value CYTO|Lipella Pharmaceuticals, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio OPTN (OptiNose Inc)|Market Value to Book Value Ratio PIRS|Market Capitalization to Book Value Procaps Group Corp PROC|PTPI: Market Capitalization to Book Value Ratio|QLI - Market Cap to Net Assets Ratio|ACELYRIN - Market Capitalization to Book Value Ratio|TFF Pharmaceuticals Inc. (TFFP) - Market Capitalization to Book Value